Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: DPP4 expression in human healthy tissues. (A) Summary of mRNA and protein expression. (B) DPP4 mRNA expression for single cell types. (C) DPP4 mRNA expression in immune cell types in the HPA dataset. (D) DPP4 mRNA expression in immune cell types in the Monaco dataset. (E) DPP4 mRNA expression in immune cell types in the Schmiedel dataset. DPP4, dipeptidyl peptidase 4; HPA, Human Protein Atlas; nTPM, normalized transcripts per kilobase per million mapped reads.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Expressing

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: DPP4 expression in human tumor tissues. (A) Overview of DPP4 RNA expression in human tumor tissues. (B) DPP4 protein expression in human tumor tissues, detected using the HPA068778 antibody. (C) DPP4 protein expression in human tumor tissues, detected using the HPA071236 antibody. (D) DPP4 protein expression in human tumor tissues, detected using the CAB045970 antibody. DPP4, dipeptidyl peptidase 4; FPKM, fragments per kilobase per million mapped; HPA, Human Protein Atlas.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Expressing, RNA Expression

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: IHC staining for DPP4 expression in human tumor tissues. (A and B) Patients with lung small cell carcinoma. (C) No staining for lung small cell carcinoma. (D and E) Patients with breast cancer. (F) No staining for breast cancer tissue. Magnification, ×100. IHC, immunohistochemistry; DPP4, dipeptidyl peptidase 4.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Immunohistochemistry, Expressing, Staining

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: Comparison of DPP4 expression between human tumor tissues and corresponding healthy tissues. (A) comparison of the DPP4 expression profiles in different types of human tumor tissues and corresponding healthy tissues. (B) Box plots showing that DPP4 expression is increased in different types of human tumor tissues compared with matched healthy tissues. (C) Box plots showing that DPP4 expression is decreased in different types of human tumor tissues compared with matched healthy tissues. (D) Validation of the upregulation of DPP4 in breast cancer tissues through western blotting. Overall survival analysis based on the DPP4 expression and Kaplan-Meier curves for (E) KIRC, (F) MESO, (G) BLCA, (H) LGG, (I) LUSC, (J) PRAD and (K) UVM, respectively. The right panel provides the full description of all types of cancer. The log rank P-value ≤0.5 was set as a difference and log rank P-value ≤0.01 was set as a significant difference. DPP4, dipeptidyl peptidase 4; KIRC, kidney renal clear cell carcinoma; MESO, mesothelioma; BLCA, bladder urothelial carcinoma; LGG, brain lower grade glioma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; UVM, uveal melanoma; HR, hazard ratio.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Comparison, Expressing, Biomarker Discovery, Western Blot

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: Distribution profiles of DPP4 expression in (A) violin plots and (B) isoform usage in bar plots in multiple types of cancer. (C) DPP4 structure in multiple types of cancer. Note: Information on nine isoforms is missing, including ENST00000413651.3, ENST00000416189.5, ENST00000434918.6, ENST00000461836.5, ENST00000468903.1, ENST00000490286.5, ENST00000491591.5, ENST00000494507.1 and ENST00000497461.5. The full names of types of cancer are shown in . DPP4, dipeptidyl peptidase 4.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Expressing

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: Methylation status of the DPP4 promoter in tumor tissues and corresponding healthy tissues. (A-D) Expression levels, methylation status at the promoter region, Pearson correlation and Spearman correlation for DPP4 in BRCA tissues and corresponding healthy tissues, respectively. (E-H) Expression levels, methylation status at the promoter region, Pearson correlation and Spearman correlation for DPP4 in COAD tissues and matched healthy tissues, respectively. (I-L) Expression levels, methylation status at the promoter region, Pearson correlation and Spearman correlation for DPP4 in THCA tissues and corresponding healthy tissues, respectively. DPP4, dipeptidyl peptidase 4; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; THCA, thyroid carcinoma.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Methylation, Expressing

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: The DPP4 DNA alterations across different types of cancer. (A) The overview of DPP4 DNA mutations across different types of cancer. Different colors present different mutation types. (B) DPP4 mRNA expression vs. its putative copy-number alterations. (C) The hot spots of DPP4 DNA mutations across different types of cancer. DPP4, dipeptidyl peptidase 4; GISTIC, Genomic Identification of Significant Targets in Cancer.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Mutagenesis, Expressing

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: Correlations of DPP4 expressions with tumor-immune systems among different types of cancer. The correlations between DPP4 expression and (A) lymphocytes, (B) chemokine, (C) receptors, (D) immunosuppressants, (E) immunostimulants and (F) MHC molecules across pan-cancers. The Y axis indicates human immune molecules, whereas the X axis indicates human types of cancer. The full names of types of cancer are shown in .

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Expressing

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: CD and m 6 2 A inhibit DPP4 expressions of both protein and mRNA in various cancer cells. CD decreases DPP4 expression in (A and D) H1975 lung cancer cells, (B and E) A549 lung cancer cells, (C and F) BT549 breast cancer cells. m 6 2 A decreases DPP4 expression in (G and J) H1975 lung cancer cells, (H and K) A549 lung cancer cells and (I and L) BT549 breast cancer cells. Panels A, B, C, G, H and I are protein expressions while panels D, E, F, J, K and L are mRNA expressions. CD, cordycepin; DPP4, dipeptidyl peptidase 4.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Expressing

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: AD inhibits DPP4 expressions of both mRNA and protein in various types of cancer cells. AD regulates DPP4 expression in (A and F) H1975 lung cancer cell line, (B and G) BT549 breast cancer cell line and (C and H) A549 lung cancer cell line. (D and I) AD regulates DPP4 expression in the PC3 prostate cancer cell line. (E, J) AD regulates DPP4 expression in the 22RV1 prostate cancer cell line. (K) Treatment with AD promotes DPP4 protein degradation in H1975 cancer cells. The left panel shows without AD treatment, while the right panel shows AD treatment. (L) The quantitative results for . The blue line shows CHX treatment only, while the red line shows CHX together with AD treatments. AD, adenosine; DPP4, dipeptidyl peptidase 4; CHX, cycloheximide.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Expressing

Journal: International Journal of Oncology

Article Title: Effect of DPP4/CD26 expression on SARS-CoV-2 susceptibility, immune response, adenosine (derivatives m 6 2 A and CD) regulations on patients with cancer and healthy individuals

doi: 10.3892/ijo.2023.5489

Figure Lengend Snippet: CD significantly inhibits syncytial formation. (A) Representative images of syncytia formation in control (CD-) and CD-treated (CD+) 293T-hACE2 cells. Magnification, ×40. (B) The quantitative results of (A) (C) DPP4 protein levels in control (CD-) and CD-treated (CD+) 293T-hACE2 cells. DPP4 (D) mRNA and (E) protein levels in 293T-hACE2 cells with different amounts of CD treatment. Unpaired student test was used for statistical analysis. ** P<0.01. CD, cordycepin; DPP4, dipeptidyl peptidase 4.

Article Snippet: Chase assay for DPP4 was performed with 20 μ g/ml cycloheximide (CHX; cat no. HY-12320; Med Chem Express Technology Co., Ltd.) and AD using H1975 cells, as previously described ( ).

Techniques: Control

Journal: bioRxiv

Article Title: Simultaneous and sequential multi-species coronavirus vaccination

doi: 10.1101/2022.05.07.491038

Figure Lengend Snippet: (A) Schematics of mRNA vaccine construct design against pathogenic human coronavirus species. Each construct has regulatory elements (5’UTR, 3’UTR and polyA) and spike ORF. The domain structures as well as engineered mutations of translated spike proteins of SARS-CoV-2 Delta variant (Delta), SARS-CoV (SARS) and MERS-CoV (MERS). (B) Engineered mutations in spike protein structures of SARS-CoV-2 Delta, SARS-CoV and MERS-CoV. The N-terminal domain (NTD, blue), receptor binding domain (RBD, green) and S2 subunit (orange) of one protomer along with homologous HexaPro mutations (pink) and Delta variant mutations (red) were highlighted in the spike trimer structures. (C) Schematics of characterization of LNP-mRNA vaccine formulations. Assembly procedure of LNP-mRNA vaccine on NanoAssemblr Ignite and downstream biophysical characterization assays. (D) Histogram displaying radius distribution of LNP-mRNA formulations of SARS-CoV-2 Delta and a Triplex (Delta + SARS + MERS) (abbreviated as Triplex-CoV or Triplex), measured by dynamic light scattering (DLS). The polydispersity index and mean radius of each LNP sample were shown at top left corner. (E) Transmission electron microscope (TEM) images of Delta and Triplex-CoV LNP-mRNAs. (F) Surface expression of functional spike proteins in 293T cells after electroporation of corresponding mRNA, as detected by human ACE2 or human DPP4 Fc fusion protein bound to PE anti-Fc antibody. (G) Schematics of vaccination schedule of the Triplex LNP-mRNA formulations, as well as downstream assays to evaluate the antibody responses and other immunological profiles. (H) Binding antibody titers of plasma samples from mice administered with PBS or different LNP-mRNAs (n = 9) against RBD or ectodomain (ECD) of SARS-CoV-2 wild type (WT, Wuhan/WA-1), Delta variant, SARS and MERS spikes. The binding antibody titers were quantified by area under curve of log 10 -transformed titration curve (log 10 AUC) in . The mice were intramuscularly injected with two doses (x2, 2 weeks apart) of PBS, 1μg SARS-CoV-2 Delta variant LNP-mRNA (delta), 1μg or 3μg equal mass mixture of Delta, SARS and MERS LNP-mRNA (Triplex-CoV). Notes: In the dot-box plots of this figure, each dot represents data from one mouse. Data are shown as mean ± s.e.m. plus individual data points in plots. Two-way ANOVA with Tukey’s multiple comparisons test was used to assess statistical significance. Statistical significance labels: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Non-significant comparisons are not shown, unless otherwise noted as n.s., not significant.

Article Snippet: To detect surface-protein expression, the cells were stained with ACE2–Fc chimera (Genscript, Z03484) or DPP4-Fc (Sino Biological, 10688-H01H) in MACS buffer (D-PBS with 2 mM EDTA and 0.5% BSA) for 30 min on ice.

Techniques: Construct, Variant Assay, Binding Assay, Transmission Assay, Microscopy, Expressing, Functional Assay, Electroporation, Transformation Assay, Titration, Injection

Journal: Viruses

Article Title: Phage-Displayed Mimotopes of SARS-CoV-2 Spike Protein Targeted to Authentic and Alternative Cellular Receptors

doi: 10.3390/v14020384

Figure Lengend Snippet: Characteristics of recombinant human cell receptors and viral spike proteins.

Article Snippet: hDPP4 , Sino Biological , 10688-H08H , D34 , P766 , 744 , 86.3.

Techniques: Recombinant, Molecular Weight

Journal: The Journal of Biological Chemistry

Article Title: Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis

doi: 10.1016/j.jbc.2022.102500

Figure Lengend Snippet: Co-localization of the identified proteins with cell membrane-bound SARS-CoV-2 spike proteins. Representative images of co-localization with SARS-CoV-2 spike proteins and the identified membrane proteins. Caco-2 cells were co-stained for SARS-CoV-2 spike protein (green) and the antibodies recognizing ACE2, CD133, Cadherin 17, DPP4, and VAPA (Red). The resulting specimens were subsequently stained with appropriate secondary antibodies and DAPI (Blue), then observed using confocal microscopy (20× objective). Co-localization is indicated in yellow in the “Merge” images. White bar: 10 μm.

Article Snippet: The ORFs of the candidate protein CDH17 and DPP4 were obtained from pCMV3-human CDH17 (HG11360-UT; Sino Biological) and pCMV3-human DPP4 (HG10688-UT; Sino Biological) by KpnI and XbaI digestion.

Techniques: Staining, Confocal Microscopy

Journal: The Journal of Biological Chemistry

Article Title: Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis

doi: 10.1016/j.jbc.2022.102500

Figure Lengend Snippet: Candidate proteins located near SARS-CoV-2 spike proteins. ( A to D ) Morphological observation of SARS-CoV-2 spike proteins and the identified membrane proteins. Caco-2 cells observed using electron microscopy. Cultured Caco-2 cells were fixed and co-stained with the SARS-CoV-2 spike protein (indicated as 20 nm particles), and candidate molecules identified. CD133 ( A ), DPP4 ( B ), CDH17 ( C ), and VAPA ( D ) are indicated as 10 nm particles. Red arrows indicate the locations of SARS-CoV-2 spike proteins. Yellow arrow heads indicate the location of each candidate protein. Scale bar; 200 or 500 nm.

Article Snippet: The ORFs of the candidate protein CDH17 and DPP4 were obtained from pCMV3-human CDH17 (HG11360-UT; Sino Biological) and pCMV3-human DPP4 (HG10688-UT; Sino Biological) by KpnI and XbaI digestion.

Techniques: Electron Microscopy, Cell Culture, Staining